Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator‐assigned therapy: A US‐based study

Abstract Background Cytomegalovirus (CMV) infections among hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients impose a significant health care resource utilization (HCRU)‐related economic burden. Maribavir (MBV), a novel anti‐viral therapy (AVT), approved by the United States Food and Drug Administration for post‐transplant CMV infections refractory (with/without resistance) to conventional AVTs has demonstrated lower hospital length of stay (LOS) versus investigator‐assigned therapy (IAT; valgancilovir, ganciclovir, foscarnet, or cidofovir) in a phase 3 trial (SOLSTICE). This study estimated the HCRU costs of MBV versus IAT. Methods An economic model was developed to estimate HCRU costs for patients treated with MBV or IAT. Mean per‐patient‐per‐year (PPPY) HCRU costs were calculated using (i) annualized mean hospital LOS in SOLSTICE, and (ii) CMV‐related direct costs from published literature. Probabilistic sensitivity analysis with Monte‐Carlo simulations assessed model robustness. Results Of 352 randomized patients receiving MBV ( n = 235) or IAT ( n = 117) for 8 weeks in SOLSTICE, 40% had HSCT and 60% had SOT. Mean overall PPPY HCRU costs of overall hospital‐LOS were $67,205 (95% confidence interval [CI]: $33,767, $231,275) versus $145,501 (95% CI: $62,064, $589,505) for MBV and IAT groups, respectively. Mean PPPY ICU and non‐ICU stay costs were: $32,231 (95% CI: $5,248, $184,524) versus $45,307 (95% CI: $3,957, $481,740) for MBV and IAT groups, and $82,237 (95% CI: $40,397, $156,945) MBV versus $228,329 (95% CI: $94,442, $517,476) for MBV and IAT groups, respectively. MBV demonstrated cost savings in over 99.99% of simulations. Conclusions This analysis suggests that Mean PPPY HCRU costs were 29%–64% lower with MBV versus other‐AVTs. image